Biohaven Ltd. (BHVN) Form 8-K — Oct 29, 2026
Biohaven reported a Q3 2026 net loss of $129.3 million ($0.86/share), improved from $173.4 million a year ago, with cash and marketable securities of approximately $164 million as of September 30, 2026. The quarter's headline items are two major licensing deals: $400 million in near-term cash from SK Biopharmaceuticals for the Kv7 platform including opakalim, and up to $100 million from Ono Pharmaceutical (with $80 million upfront already received) for the MoDE IgG degrader portfolio in Asia, plus roughly 20% royalties.
Key figures
- Total Debt
- 264294000
- Total Assets
- 263676000
- Cash Position
- 164000000
- Ga expense q3
- 24600000
- Rd expense q3
- 101900000
- Cash q3 2025 note
- cash and equivalents $95.8M plus marketable securities $65.4M at 9/30/26
- Ono near term payments
- up to $100 million ($80M received, $20M milestone), ~20% royalties
- Skbp cash consideration
- $400 million ($350M at closing, $50M one year later) plus up to $150M milestones
- Yale biohaven litigation award
- $4 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.